285 related articles for article (PubMed ID: 35171029)
1. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
3. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
4. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
5. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
6. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
9. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
11. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
12. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
16. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M
BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353
[TBL] [Abstract][Full Text] [Related]
18. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
19. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a new HPV genotyping assay based on next-generation sequencing.
Yi X; Zou J; Xu J; Liu T; Liu T; Hua S; Xi F; Nie X; Ye L; Luo Y; Xu L; Du H; Wu R; Yang L; Liu R; Yang B; Wang J; Belinson JL
Am J Clin Pathol; 2014 Jun; 141(6):796-804. PubMed ID: 24838323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
